BioSpace News Archive

Obalon Therapeutics, Inc. announces that it has entered into a new common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor, for up to $15 million.

PDO MAX, INC is pleased to announce that it has received 510 clearance from the Food and Drug Administration for its brand of PDO absorbable threads in cannula.

Flexion Therapeutics, Inc. announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units.

Feb. 7, 2020 21:30 UTC The addition of three lab locations complements Zoetis’ growing reference laboratory footprint and enhances its value to veterinarians in the U.S. PARSIPPANY, N.J. & WOBURN, Mass.--( BUSINESS WIRE )-- Zoetis Inc . (NYSE:ZTS) today announced the acquisition of Ethos Diagnostic Science, a veterinary reference lab business dedicated to serving leading specialty animal hospitals, the greater veterinary community and researchers with accurate, reliabl

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 5, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 78,875 shares of Puma common stock to 14 new non-executive employees.

Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and their respective subsidiaries (KFHP/H) reported 2019 annual financial results. Total operating revenues for 2019 were $84.5 billion , compared to $79.7 billion in 2018. Operating expenses were $81.8 billion , compared to $77.8 billion in the prior year. Ope

Shields provides specialty pharmacy services to hospitals and other covered entities. On October 24, 2019, Shields learned of suspicious activity related to an employee’s email account.

Feb. 7, 2020 23:20 UTC Data presented at the 9 th Annual Glaucoma 360 New Horizons Forum CINCINNATI--( BUSINESS WIRE )-- Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that Kevin Peters, M.D., Aerpio’s Chief Scientific Officer, presented data from the fifth cohort of subjects from a Phase 1b trial showing the potential of a topical ocu

Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces the following changes to its Board of Directors, effective today.

The Phantom® ActivCore Nail addresses TTC arthrodesis and is the second of three hindfoot fusion nailing systems Paragon 28® plans to launch in 2020.